All In Biotech

Drug Trial Radar · NCT03226522

Addressing Dementia Via Agitation-Centered Evaluation

A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

366

Actual

Start

Jul 13, 2017

Primary completion

Apr 17, 2020

Study completion Apr 17, 2020

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

Conditions

  • Agitation in Patients With Dementia of the Alzheimer's Type
  • Alzheimer Disease
  • Agitation,Psychomotor

Interventions

  • AXS-05Drug

    AXS-05

  • BupropionDrug

    Bupropion

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in CMAI Total ScoreTime frame: 5 weeks

Locations

78 sites in 2 countries. Site status is shown where the registry gives one.

  • Axsome Study Site

    Gilbert, Arizona

  • Axsome Study Site

    Phoenix, Arizona

  • Axsome study site

    Scottsdale, Arizona

  • Axsome study site

    Scottsdale, Arizona

  • Axsome Study Site

    Tucson, Arizona

  • Axsome Study Site

    Little Rock, Arkansas

  • Axsome study site

    Canoga Park, California

  • Axsome study site

    Costa Mesa, California

  • Axsome study site

    Fresno, California

  • Axsome study site

    Long Beach, California

  • Axsome study site

    Long Beach, California

  • Axsome Study Site

    Los Alamitos, California

  • Axsome study site

    Riverside, California

  • Axsome study site

    Sacramento, California

  • Axsome study site

    Santa Ana, California

  • Axsome Study Site

    Santa Clarita, California

  • Axsome study site

    Sherman Oaks, California

  • Axsome study site

    Simi Valley, California

  • Axsome study site

    Temecula, California

  • Axsome study site

    Ventura, California

  • Axsome Study Site

    Colorado Springs, Colorado

  • Axsome study site

    Cromwell, Connecticut

  • Axsome study site

    New London, Connecticut

  • Axsome Study Site

    Apopka, Florida

  • Axsome study site

    Boca Raton, Florida

  • Axsome study site

    Boynton Beach, Florida

  • Axsome Study Site

    Coconut Creek, Florida

  • Axsome Study Site

    Greenacres City, Florida

  • Axsome study site

    Hallandale, Florida

  • Axsome study site

    Hialeah, Florida

  • Axsome Study Site

    Lake City, Florida

  • Axsome study site

    Miami, Florida

  • Axsome study site

    Miami, Florida

  • Axsome Study Site

    Orlando, Florida

  • Axsome study site

    Pensacola, Florida

  • Axsome Study Site

    Port Orange, Florida

  • Axsome study site

    Spring Hill, Florida

  • Axsome study site

    Tampa, Florida

  • Axsome study site

    Tampa, Florida

  • Axsome study site

    Atlanta, Georgia

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.